Tofacitinib-Induced Modulation of Intestinal Adaptive and Innate Immunity and Factors Driving Cellular and Systemic Pharmacokinetics

• Published in: Cellular and molecular gastroenterology and hepatology Vol. 13; no. 2; pp. 383 - 404
• Main Authors: Texler, Bernhard, Zollner, Andreas, Reinstadler, Vera, Reider, Simon J., Macheiner, Sophie, Jelusic, Barbara, Pfister, Alexandra, Watschinger, Christina, Przysiecki, Nicole, Tilg, Herbert, Oberacher, Herbert, Moschen, Alexander R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2022; Elsevier
• Subjects: inflammatory bowel disease; JAK inhibitor; mucosal inflammation; Original Research; pharmacokinetics; tofacitinib; M-CSF; DI; IHC; PHA; ENT; IBD; mRNA; mucosal inflammation; LPS; UC; tofacitinib; LC-MS/MS; Th; FSC; JAKi; pharmacokinetics; JAK inhibitor; IFNγ; PBS; CD; IL; ASV; DSS; IEC; CFSE; PBMC; inflammatory bowel disease; 3D; STAT; TNF-α; JAK; PI; ATP; ELISA

By interfering with multiple cytokines, human Janus kinase inhibitors (JAKis) are of growing importance in the treatment of malignant and inflammatory conditions. Although tofacitinib has demonstrated efficacy as the first-in-class JAKi in ulcerative colitis many aspects concerning its mode of actio...